Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Abstract

BACKGROUND Converging lines of evidence suggest that microglia are relevant to Parkinson's disease pathogenesis, justifying exploration of therapeutic agents thought to attenuate pathogenic microglial function. We sought to test the safety and efficacy of NLY01-a brain-penetrant, pegylated, longer-lasting version of exenatide (a glucagon-like peptide-1 receptor agonist) that is believed to be anti-inflammatory via reduction of microglia activation-in Parkinson's disease. METHODS We report a 36-week, randomised, double-blind, placebo-controlled study of NLY01 in participants with early untreated Parkinson's disease conducted at 58 movement disorder clinics in the USA. Participants meeting UK Brain Bank or Movement Disorder Society research criteria for Parkinson's disease were randomly allocated (1:1:1) to one of two active treatment groups (2·5 mg or 5·0 mg NLY01) or matching placebo, based on a central computer-generated randomisation scheme using permuted block randomisation with varying block sizes. All participants, investigators, coordinators, study staff, and sponsor personnel were masked to treatment assignments throughout the study. The primary efficacy endpoint for the primary analysis population (defined as all randomly assigned participants who received at least one dose of study drug) was change from baseline to week 36 in the sum of Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts II and III. Safety was assessed in the safety p…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(23)00378-2

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Cited by

See all 170

Metadata

Authors
McGarry, A., Rosanbalm, S., Leinonen, M., Olanow, C. W., To, D., Bell, A., Lee, D., Chang, J., Dubow, J., Dhall, R., Burdick, D., Parashos, S., Feuerstein, J., Quinn, J., Pahwa, R., Afshari, M., Ramirez-Zamora, A., Chou, K., Tarakad, A., Luca, C., Klos, K., Bordelon, Y., St Hiliare, M.-H., Shprecher, D., Lee, S., Dawson, T. M., Roschke, V., & Kieburtz, K.
Affiliations
  • Cooper Medical School of Rowan University (US)
  • Rho (United States) (US)
  • University of Arkansas for Medical Sciences (US)
  • University of Colorado Hospital (US)
  • Oregon Health & Science University (US)
  • University of Kansas Medical Center (US)
  • Rush University Medical Center (US)
  • University of Michigan (US)
  • Baylor College of Medicine (US)
  • University of Miami Health System (US)
  • University of California, Los Angeles (US)
  • Banner Health (US)
  • Johns Hopkins University (US)
Corresponding author
McGarry, Andrew
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2024-01
Volume
23
Issue
1
Pages
37-45
ISSN
1474-4422 (ISSN-L)
OpenAlex
W4389657185
Cited by
153
References
24
Citations by year
2026: 53 · 2025: 65 · 2024: 34
FWCI
25.90
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
exenatide, GLP-1 receptor agonists, Parkinson's disease, microglial activation, neuroinflammation, anti-inflammatory therapy, MDS-UPDRS, safety and tolerability, adverse events, sleepiness, suicidality, impulsivity
MeSH terms
Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Double-Blind Method, Humans, Parkinson Disease, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s1474-4422(23)00378-2
The paper
McGarry, A., Rosanbalm, S., Leinonen, M., Olanow, C. W., To, D., Bell, A., Lee, D., Chang, J., Dubow, J., Dhall, R., Burdick, D., Parashos, S., Feuerstein, J., Quinn, J., Pahwa, R., Afshari, M., Ramirez-Zamora, A., Chou, K., Tarakad, A., . . . Kieburtz, K. (2024). Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(23)00378-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.